Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760344 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study of Diabetes Mellitus, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 386
- Enrollment target
- 20
- Study locations
NCT00760344 is a Phase 2 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 386 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00760344, a Phase 2 study of Diabetes Mellitus, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 386 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SYR-472
Study Locations (20)
California
- - Carmichael
- - Chino
- - Long Beach
- - Los Angeles
- - Los Gatos
- - Orange
- - Pico Rivera
- - Rolling Hills Estates
- - Roseville
- - Rowland Heights
- - Sacramento
Alabama
- - Birmingham
- - Mobile
- - Montgomery
Arizona
- - Phoenix
- - Tempe
- - Tucson
Arkansas
- - Anderson
- - Little Rock
- - Pine Bluff
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00760344
The ClinicalTrials.gov registry entry for NCT00760344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (79% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00760344 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00760344 about?
NCT00760344 is a clinical study titled "Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
What is the current status of trial NCT00760344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 386 participants. The study started on 2007-03. Estimated completion is 2008-03.
What conditions does trial NCT00760344 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT00760344?
The interventions under investigation include: Placebo (DRUG), SYR-472 (DRUG).
Who is sponsoring clinical trial NCT00760344?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00760344 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
RECRUITING · Phase 2
-
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus
RECRUITING · Phase 2
-
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.